Peptide Inhibiting Alpha-Synuclein v-SNARE Binding

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for neurodegenerative diseases like Parkinson's, particularly those targeting alpha-synuclein oligomers, face limitations due to non-specific binding and low permeability across the blood-brain barrier, failing to effectively inhibit neural toxicity caused by the interaction between alpha-synuclein oligomers and v-SNARE proteins.

Innovation Solution

Development of specific peptides, such as those with amino acid sequences SEQ ID NO: 1, 2, 3, and 4, that inhibit the binding of alpha-synuclein oligomers and v-SNARE proteins, thereby reducing neural toxicity and exhibiting preventive and therapeutic effects for neurodegenerative diseases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antibodies are used to inhibit alpha-synuclein oligomers, then the binding inhibition is achieved, but the blood-brain barrier permeability is low and specificity is poor

Engineering Contradiction:

Improvebinding inhibition efficacyVSAvoidblood-brain barrier permeability

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the molecular parameters by switching from large antibody molecules to small peptide molecules (SEQ ID NO: 1), fundamentally altering size, charge distribution, and structural flexibility to achieve both blood-brain barrier penetration and specific binding to alpha-synuclein oligomers

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent extracts the essential binding function from complex antibodies and implements it through simplified peptide sequences that specifically recognize alpha-synuclein oligomers without the unwanted side effects of antibody size and non-specific binding

Inventive Principle:

Principle #2Taking out (Extraction)

2Reliability

If antibodies are used to inhibit alpha-synuclein oligomers, then the binding inhibition is achieved, but the specificity to oligomers is poor

Engineering Contradiction:

Improvebinding inhibition efficacyVSAvoidoligomer binding specificity

Core Design Contradiction:

ReliabilityVSMeasurement precision

Solution Approach 1:

The patent applies local quality by designing specific regions within the peptide sequence (SEQ ID NO: 1) that are optimized for oligomer recognition, creating localized binding motifs that provide high specificity while maintaining overall peptide flexibility for blood-brain barrier penetration

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS20230331794A1Peptide for preventing or treating neurodegenerative diseases and pharmaceutical composition comprising same

Publication Date: 2023.10.19 SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

AI summary

The present invention relates to a peptide which can prevent and treat a neurodegenerative disease and a pharmaceutical composition comprising the peptide. The peptide of the present invention inhibits the binding of v-SNARE protein and alpha-synuclein oligomers, thus lowering neural toxicity caused by the alpha-synuclein oligomers and allowing effective use in the development of therapeutic agents for a neurodegenerative disease such as Parkinson’s disease.